Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration Resistant Prostate Cancer.
Winquist E, Hotte SJ, Chi K, Sridhar S, Ellard S, Ong M, Iqbal N, Salim M, Emmenegger U, Gingerich JR, Lalani AK, Major P, Kollmannsberger C, Yip S, Hansen A, Finch D, Canil C, Hutchenreuther J, Vera-Badillo F, Smoragiewicz M, Cabanero M, Tsao MS, Ritch E, Wyatt AW, Seymour L.
Winquist E, et al. Among authors: smoragiewicz m.
Clin Cancer Res. 2024 Nov 8. doi: 10.1158/1078-0432.CCR-24-1612. Online ahead of print.
Clin Cancer Res. 2024.
PMID: 39513948